Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.52 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.46 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | ACP3 | P15309 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL667745 | 1.00 | MEN1 (0.56) | MEN1HPGDKMT2AL3MBTL1TSHR | |
| Hydrochloric Acid SCHEMBL3861536 | 1.00 | MEN1 (0.56) | MEN1HPGDKMT2AL3MBTL1TSHR | |
| Hydrochloric Acid SCHEMBL6359108 | 1.00 | MEN1 (0.56) | MEN1HPGDKMT2AL3MBTL1TSHR | |
| SCHEMBL2433538 | 0.98 | TSHR (0.57) | MEN1HPGDKMT2AL3MBTL1TSHR | |
| SCHEMBL3858019 | 0.98 | TSHR (0.57) | MEN1HPGDKMT2AL3MBTL1TSHR | |
| SCHEMBL3474257 | 0.98 | TSHR (0.57) | MEN1HPGDKMT2AL3MBTL1TSHR | |
| SCHEMBL6359586 | 0.98 | TSHR (0.57) | MEN1HPGDKMT2AL3MBTL1TSHR | |
| SCHEMBL6359584 | 0.98 | TSHR (0.57) | MEN1HPGDKMT2AL3MBTL1TSHR | |
| Hydrochloric Acid SCHEMBL7787578 | 0.85 | CYP19A1 (0.48) | MEN1HPGDKMT2AL3MBTL1TSHR | |
| SCHEMBL254876 | 0.83 | TSHR (0.61) | MEN1HPGDKMT2AL3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1310870-C | Enantiomerically enriched 1-phenylethylamines | BAYER CHEMICALS AG (DE) | 2007-04-18 | — | — | CN | claimed |
| US-20050131073-A1 | Enantiomerically enriched 1-phenylethylamines | LANXESS DEUTSCHLAND GMBH (DE) | 2005-06-16 | — | — | US | claimed |
| CN-1603302-A | Enantiomerically enriched 1-phenylethylamines | BAYER CHEMICALS AG (DE) | 2005-04-06 | — | — | CN | claimed |
| EP-3356348-B1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | SENTINEL ONCOLOGY LTD (GB) | 2021-05-05 | — | — | EP | disclosed |
| CN-108473472-B | 2-aminoquinazoline derivatives as P70S6kinase inhibitors | 圣提内尔肿瘤学有限公司 | 2021-02-12 | — | — | CN | disclosed |
| US-10730882-B2 | 2-aminoquinazoline derivatives as P70S6 kinase inhibitors | SENTINEL ONCOLOGY LIMITED (GB) | 2020-08-04 | — | — | US | disclosed |
| US-20190292195-A1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2019-09-26 | — | — | US | disclosed |
| US-10344033-B2 | 2-aminoquinazoline derivatives as P70S6 kinase inhibitors | SENTINEL ONCOLOGY LIMITED (GB) | 2019-07-09 | — | — | US | disclosed |
| US-20180370975-A1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2018-12-27 | — | — | US | disclosed |
| EP-3356348-A1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | Sentinel Oncology Limited (GB) | 2018-08-08 | — | — | EP | disclosed |
| CN-102317269-B | Novel amino aza heterocyclic carboxamides | MERCK PATENT GMBH | 2015-06-17 | — | — | CN | disclosed |
| CN-102317269-A | Novel amino aza heterocyclic carboxamides | MERCK PATENT GMBH | 2012-01-11 | — | — | CN | disclosed |
| CN-101611019-A | The big ring serum prothrombin conversion accelerator (SPCA) a inhibitor that can be used as anticoagulant | BRISTOL MYERS SQUIBB CO (US) | 2009-12-23 | — | — | CN | disclosed |
| EP-2102176-A2 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | Brystol-Myers Squibb Company (US) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008079836-A2 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-03 | — | — | WO | disclosed |
| CN-1310870-C | Enantiomerically enriched 1-phenylethylamines | BAYER CHEMICALS AG (DE) | 2007-04-18 | — | — | CN | disclosed |
| US-20050131073-A1 | Enantiomerically enriched 1-phenylethylamines | LANXESS DEUTSCHLAND GMBH (DE) | 2005-06-16 | — | — | US | disclosed |
| CN-1603302-A | Enantiomerically enriched 1-phenylethylamines | BAYER CHEMICALS AG (DE) | 2005-04-06 | — | — | CN | disclosed |
| EP-1505056-A1 | Enantiomerically enriched 1-phenylethylamines | Bayer Chemicals AG (DE) | 2005-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292195-A1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | RPS6KA1, MTOR, RPTOR | ACHE 4657/4885CA2 2276/4885HSP90AA1 1208/4885 |
| US-20050131073-A1 | Enantiomerically enriched 1-phenylethylamines | PNMT, COMT, ADRA1A | ACHE 322/4885CA2 4783/4885HSP90AA1 4044/4885 |
| US-20180370975-A1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | RPS6KA1, MTOR, RPTOR | ACHE 4657/4885CA2 2276/4885HSP90AA1 1208/4885 |
| US-10344033-B2 | 2-aminoquinazoline derivatives as P70S6 kinase inhibitors | RPS6KA1, MTOR, RPTOR | ACHE 4657/4885CA2 2276/4885HSP90AA1 1208/4885 |
| US-10730882-B2 | 2-aminoquinazoline derivatives as P70S6 kinase inhibitors | RPS6KA1, MTOR, RPTOR | ACHE 4657/4885CA2 2276/4885HSP90AA1 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.